≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Chromophobe cell carcinoma of kidney

Endpoint Browser PheWeb

C3_KIDNEY_CHROMOPHOBE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cancer registry: Topography ICD-O-3 — C64
  • Cancer registry: Morphology ICD-O-3 — 8317
  • Cancer registry: Behaviour codes — 3

1 out of 7 registries used, show all original rules.

182

4. Check minimum number of events

None

182

5. Include endpoints

None

182

6. Filter based on genotype QC (FinnGen only)

173

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF9
Name in latin
Carcinoma in situ labii (oris)

Case counts by codes

↥

FinnGen case counts by registry codes:

Not enough data for upset plot.

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 173 63 110
Unadjusted period prevalence (%) 0.04 0.02 0.05
Median age at first event (years) 67.85 65.37 69.27

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
182
Matched controls
1820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8317/3-C64.9
ICD-O-3
Renal cell carcinoma, chromophobe type of kidney, NOS
+∞
263.4
182
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
235.1
171
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
1128.8
189.1
155
9
JN4AD
NOMESCO Finland
Body CT examination
17.3
61.3
58
48
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
21.2
60.4
50
32
B01AB10
ATC
tinzaparin; parenteral
13.9
55.0
60
62
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
+∞
55.0
50
*
KAD01
NOMESCO Finland
Percutaneous endoscopic partial nephrectomy
604.8
48.7
46
*
KAD00
NOMESCO Finland
Partial nephrectomy
238.4
38.4
38
*
JN4BD
NOMESCO Finland
Extensive body CT
12.5
36.7
40
40
WX408
NOMESCO Finland
General anesthesy, balanced
6.6
36.1
92
244
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
70.3
34.9
39
7
KAC10
NOMESCO Finland
Total nephrectomy with capsule
+∞
31.1
29
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.9
30.2
59
119
WX302
NOMESCO Finland
Thoracal epidural anesthesy
32.7
29.9
39
15
TPH07
NOMESCO Finland
Cathetrisation of artery
6.7
29.4
59
122
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
+∞
28.9
27
*
JN4CD
NOMESCO Finland
Very extensive body CT
50.9
25.5
30
7
130
Kela drug reimbursment
Malignant tumour
+∞
23.4
22
*
WX402
NOMESCO Finland
General anaesthesia
4.7
20.0
61
177
B01AB05
ATC
enoxaparin; parenteral
4.0
19.5
92
367
U75
ICPC
Malignant neoplasm of kidney
+∞
19.1
18
*
ZXE20
NOMESCO Finland
More than three and less than five hours
4.9
17.4
46
118
KA1AE
NOMESCO Finland
Kidney ultrasound examination
15.6
16.6
27
20
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.8
16.4
121
629
R4110
NOMESCO Finland
Physiotherapy
3.5
15.0
75
301
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
14.8
14
*
WZC30
NOMESCO Finland
Teaching
4.4
14.4
43
120
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
13.6
14.1
24
20
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
13.7
13
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.2
13.5
87
403
H02AB02
ATC
dexamethasone; systemic
31.0
13.2
17
6
N02AX02
ATC
tramadol; systemic, rectal
3.0
12.0
106
577
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
11.6
11
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.5
11.3
47
164
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
63.8
10.8
12
*
Z51.5
ICD-10 Finland
Palliative care
9.3
10.4
21
25
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.2
9.9
29
79
N02BE01
ATC
paracetamol; systemic, rectal
6.8
9.9
175
1432
116
Kela drug reimbursment
Prostate cancer
+∞
9.5
9
*
197
Kela drug reimbursment
Sunitinib
+∞
9.5
9
*
S18
ICPC
Laceration/cut
2.6
9.2
104
615
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
38.8
9.1
11
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
21.3
8.6
12
6
WZC00
NOMESCO Finland
Treatment plan or consultation
2.7
8.6
62
293
Y77
ICPC
Malignant neoplasm prostate
+∞
8.4
8
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
8.4
8
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
8.4
8
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.2
8.4
24
64
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
10.8
8.2
15
15
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
10.8
8.2
15
15
JN3AD
NOMESCO Finland
Abdominal CT examination
3.6
8.1
29
91
WF002
NOMESCO Finland
Radical radiotherapy
47.0
7.8
9
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.8
7.7
25
73
XKD00
NOMESCO Finland
Uroflowmetry
2.8
7.4
44
187
L01XE04
ATC
[U] sunitinib
+∞
7.3
7
*
KA3LT
NOMESCO Finland
Njurlesion coagulation
+∞
7.3
7
*
KAC00
NOMESCO Finland
Nephrectomy
+∞
7.3
7
*
SPAT1153
SPAT
Removal of sutures
2.4
7.3
73
398
ZXE30
NOMESCO Finland
More than five and less than seven hours
8.3
6.8
14
18
XX3DW
NOMESCO Finland
Time consuming IT work
5.6
6.5
18
35
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
72.3
6.5
7
*
L02AE02
ATC
leuprorelin; implant, parenteral
72.3
6.5
7
*
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
11.6
6.4
11
10
3012
Kela drug reimbursment
Cabozantinib
+∞
6.3
6
*
D41.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Renal pelvis
+∞
6.3
6
*
1502
Kela drug reimbursment
Cabozantinib
+∞
6.3
6
*
115
Kela drug reimbursment
Breast cancer
+∞
6.3
6
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
6.3
6
*
ZXC96
NOMESCO Finland
Robot assisted procedure
27.7
6.3
8
*
ZXA00
NOMESCO Finland
Right side
2.3
6.2
62
333

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
79
41
33.28
107.85
1.2
1.3
—
—
—
0
0
146
607
8.10
34.39
2.6
2.4
—
—
—
0
0
119
419
6.32
33.53
2.5
1.6
—
—
—
0
0
39
51
9.46
29.26
3.1
2.2
0.25
0.26
g/l
0.03
29
18
139
634
6.05
26.91
9.2
5.3
1.19
1.21
mmol/l
1.61
131
576
64
172
5.20
23.42
6.1
7.1
97.22
94.85
%
3.28
64
167
44
87
6.35
22.52
6.7
9.1
—
—
—
0
0
97
379
4.34
21.61
4.1
2.5
—
—
—
0
0
65
188
4.82
21.56
6.1
6.9
-0.41
1.46
mmol/l
3.55
55
154
65
192
4.71
20.93
6.4
6.1
105.52
104.04
mmol/l
1.53
65
192
97
395
4.12
20.05
4.2
2.7
0.07
0.43
e6/l
4.50
74
289
126
619
4.37
19.82
6.7
3.6
35.66
35.72
g/l
0.04
119
573
52
134
5.03
19.70
8.0
7.6
—
—
—
0
0
99
416
4.03
19.41
2.2
2.2
—
—
—
0
0
101
431
4.02
19.35
4.4
2.8
326.43
207.68
e6/l
0.13
77
325
132
697
4.25
18.10
9.8
5.7
1.20
1.21
mmol/l
0.73
110
610
43
102
5.21
17.84
1.4
1.1
—
—
—
0
0
105
497
3.63
16.49
5.0
3.4
41.30
82.63
e6/l
0.74
82
351
65
230
3.84
15.85
3.7
2.8
0.90
1.65
e6/l
0.44
34
121
169
1132
7.90
15.57
11.2
5.5
80.86
75.28
u/l
0.87
163
1043
91
405
3.49
15.54
7.4
3.2
7.38
7.40
ph
0.95
19
58
72
289
3.47
14.28
3.3
2.1
2.36
3.96
e6/l
1.83
64
260
52
174
3.78
13.54
8.4
5.4
1.04
1.03
mmol/l
0.06
47
162
123
714
3.23
12.59
11.1
15.6
1.22
1.34
inr
0.77
36
173
31
75
4.78
12.36
3.1
1.4
50.28
2.46
ug/l
0.51
21
62
150
997
3.87
11.93
5.0
4.0
—
—
—
0
0
86
432
2.88
11.04
5.2
2.0
2.38
2.34
mmol/l
1.69
77
363
126
788
2.95
10.44
10.6
6.5
4.18
4.39
e9/l
0.58
106
696
80
407
2.72
9.76
2.7
2.9
—
—
—
0
0
59
266
2.80
8.99
3.4
2.7
574.54
561.93
mosm/kgh2o
0.18
50
221
55
243
2.81
8.67
1.6
2.0
30.19
29.62
s
0.38
55
235
65
322
2.58
8.11
1.3
1.2
—
—
—
0
0
72
380
2.48
7.81
3.7
4.1
—
—
—
0
0
56
265
2.61
7.61
4.7
2.1
2.48
2.42
mmol/l
2.62
51
224
32
112
3.25
7.52
5.6
4.0
129.59
86.62
ng/l
1.15
27
99
174
1488
4.85
6.88
20.1
12.7
36.48
23.08
mg/l
3.93
163
1135
20
54
4.04
6.85
2.5
1.9
—
—
—
0
0
40
185
2.49
5.56
4.2
2.6
26.09
23.84
%
0.50
33
158
26
113
2.52
4.08
4.6
4.8
—
—
—
0
0
138
1105
2.03
4.06
4.6
4.2
15.03
12.03
mm/h
1.48
129
1002
174
1569
3.48
3.97
21.5
12.3
—
—
—
0
0
55
333
1.93
3.81
8.8
4.4
—
—
—
0
0
7
8
9.04
3.80
1.0
1.1
—
—
—
0
0
137
1120
1.90
3.46
5.0
4.1
—
—
—
0
0
79
551
1.77
3.42
3.9
3.3
1428.95
190.76
mg/l
0.70
53
348
97
718
1.75
3.41
4.2
3.5
0.00
0.00
estimate
-0.00
28
94
95
703
1.74
3.31
5.5
4.8
0.00
0.00
estimate
-0.00
27
102
22
100
2.37
3.14
4.3
2.9
—
—
—
0
0
89
657
1.69
3.05
6.1
6.1
—
—
—
0
0
79
566
1.70
3.02
3.7
3.2
7.21
7.79
mmol/l
0.41
64
476
87
640
1.69
3.01
12.0
7.7
0.00
0.00
e9/l
-0.00
73
525
93
699
1.68
2.95
4.3
3.5
0.00
0.01
estimate
0.50
28
114
80
578
1.69
2.95
4.4
3.9
15.79
9.96
mg/mmol
0.59
50
361
7
13
5.55
2.89
1.7
1.1
—
—
—
0
0
5
6
8.52
2.76
3.2
1.5
8.74
2.50
mg/l
—
5
6
95
729
1.63
2.71
5.8
5.5
1.75
1.84
e9/l
0.48
81
649
11
35
3.28
2.69
3.2
1.2
41.34
35.05
mg/l
0.15
11
28
11
35
3.28
2.69
3.2
1.2
62.62
51.94
mg/l
0.12
11
27
95
730
1.63
2.68
5.9
5.8
0.20
0.20
e9/l
0.11
80
649
93
711
1.63
2.68
5.9
5.4
0.61
0.59
e9/l
0.32
79
621
93
712
1.63
2.66
5.9
5.4
0.04
0.04
e9/l
0.32
80
624
12
42
2.99
2.60
2.9
3.0
—
—
—
0
0
8
20
4.13
2.60
3.6
3.4
—
—
—
0
0
5
7
7.30
2.56
1.0
1.0
13.14
5.63
nmol/l
—
5
7
8
21
3.93
2.49
1.1
1.2
—
—
—
0
0
174
1618
2.71
2.49
14.1
9.3
26.22
26.47
u/l
0.06
169
1547
55
374
1.67
2.48
4.9
3.6
0.00
0.03
estimate
0.50
26
96
60
420
1.64
2.41
4.0
2.5
399.15
11172.93
umol/l
2.71
52
372
8
22
3.75
2.39
2.5
1.0
—
—
—
0
0
59
416
1.62
2.29
3.0
2.7
0.69
0.77
ug/l
0.49
44
280
20
101
2.10
2.26
2.1
1.2
—
—
—
0
0
16
74
2.27
2.22
1.4
1.6
—
—
—
0
0
8
24
3.44
2.21
1.5
1.2
—
—
—
0
0
77
583
1.56
2.20
3.4
2.7
273.47
139.62
ug/l
1.13
68
538
28
165
1.82
2.06
6.3
3.3
5.91
5.75
kpa
0.49
28
157
22
120
1.95
2.03
2.5
1.3
67.97
66.88
g/l
0.28
22
107
48
332
1.61
1.99
4.2
3.5
—
—
—
0
0
5
11
4.64
1.95
1.0
1.0
—
—
—
0
0
6
16
3.84
1.95
2.2
1.3
—
—
—
0
0
23
131
1.87
1.88
1.7
1.4
—
—
—
0
0
7
23
3.12
1.82
1.6
2.5
—
—
—
0
0
18
100
1.89
1.60
3.0
4.6
0.40
0.08
%
—
5
26
43
307
1.52
1.54
1.6
1.7
1.25
1.08
mg/l
0.23
33
242
91
755
1.41
1.49
5.1
4.0
4.25
2.03
ug/l
0.49
82
673
127
1118
1.45
1.48
4.7
3.6
15.16
14.78
pmol/l
1.00
118
1001
165
1537
1.79
1.48
5.1
4.9
4.42
4.55
mmol/l
0.82
151
1418
21
126
1.75
1.48
4.6
3.0
—
—
—
0
0
22
134
1.73
1.47
1.9
1.6
—
—
—
0
0
6
22
2.78
1.44
2.3
3.5
56.17
60.18
%
—
6
22
6
22
2.78
1.44
2.3
2.7
3.63
5.02
e9/l
—
6
22
6
23
2.66
1.38
1.2
1.2
—
—
nmol/l
—
0
0
6
23
2.66
1.38
3.3
2.4
—
—
—
0
0
5
17
2.99
1.37
1.8
1.5
31.00
32.94
pg
—
5
17
163
1523
1.67
1.31
5.0
4.9
1.35
1.43
mmol/l
1.60
149
1394
10
48
2.15
1.30
1.9
1.1
38.28
37.41
g/l
—
10
40
167
1571
1.76
1.29
5.6
5.5
2.61
2.67
mmol/l
0.44
151
1445
151
1388
1.52
1.29
5.6
4.4
1.98
2.00
mu/l
0.06
137
1247
5
18
2.83
1.29
3.0
4.1
—
—
—
0
0
18
108
1.74
1.28
3.1
4.4
1.60
0.74
%
—
5
34
29
198
1.55
1.27
1.3
1.3
711.11
565.93
titre
—
9
54
49
377
1.41
1.20
3.9
3.2
—
—
—
0
0
158
1475
1.54
1.16
6.6
6.4
39.59
40.79
mmol/mol
0.99
147
1374
158
1479
1.52
1.09
4.4
4.4
1.38
1.31
mmol/l
0.58
143
1341
161
1513
1.56
1.09
5.6
4.9
6.12
6.06
mmol/l
0.20
150
1368
20
131
1.59
1.05
4.0
3.4
—
—
—
0
0
14
84
1.72
1.01
1.1
1.2
136.74
86.33
iu/ml
—
5
33
5
23
2.21
0.98
1.0
1.3
—
—
—
0
0
23
159
1.51
0.97
1.7
1.7
—
—
—
0
0
46
363
1.36
0.96
2.8
2.1
3.03
3.06
mg/l
0.04
37
307
53
430
1.33
0.93
2.1
1.7
1.50
1.35
mmol/l
0.53
43
366
27
196
1.44
0.91
1.3
1.2
—
—
—
0
0
0
26
0.00
0.79
0.0
2.5
—
—
—
0
0
47
384
1.30
0.78
1.7
1.6
15.75
20.50
nmol/l
1.90
40
330
0
27
0.00
0.78
0.0
2.4
—
4.17
—
0
27
0
27
0.00
0.78
0.0
2.4
—
105.70
—
0
27
9
53
1.73
0.77
1.3
1.5
—
—
—
0
0
12
181
0.64
0.74
1.3
1.5
—
—
—
0
0
19
136
1.44
0.70
3.9
2.6
3.91
4.44
kpa
0.77
19
127
39
317
1.29
0.67
1.7
1.7
1262.08
1205.39
nmol/l
0.13
25
247
5
30
1.68
0.62
1.0
1.7
—
—
—
0
0
0
20
0.00
0.60
0.0
2.5
—
578.91
—
0
11
0
20
0.00
0.60
0.0
1.8
—
—
—
0
0
0
21
0.00
0.60
0.0
1.3
—
183.26
—
0
21
20
151
1.36
0.57
3.2
3.5
310.25
216.23
ng/l
0.32
20
137
17
126
1.39
0.54
2.7
2.3
13.50
15.42
nmol/l
0.23
12
113
28
225
1.29
0.53
1.0
1.3
4.40
15.55
u/ml
1.35
11
80
18
135
1.37
0.53
1.6
2.0
75.36
67.77
e9/l
0.50
11
106
19
144
1.36
0.53
1.1
1.3
—
—
—
0
0
6
40
1.52
0.52
1.3
1.7
—
—
—
0
0
6
40
1.52
0.52
2.3
2.8
—
—
—
0
0
70
627
1.19
0.50
3.7
3.6
124.71
99.88
ng/l
0.11
54
449
5
81
0.61
0.47
3.6
3.8
—
—
—
0
0
8
56
1.45
0.43
1.6
1.8
—
—
—
0
0
5
32
1.58
0.42
1.2
1.0
—
—
—
0
0
72
655
1.16
0.42
2.0
2.1
96.59
93.48
pmol/l
0.19
33
345
5
33
1.53
0.41
2.4
3.1
7.42
7.42
ph
—
5
26
5
33
1.53
0.41
1.6
4.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
7.63
—
0
11
0
17
0.00
0.41
0.0
6.9
—
12.39
—
0
17
10
71
1.43
0.40
6.0
4.0
—
—
—
0
0
6
42
1.44
0.36
1.7
1.1
—
—
—
0
0
28
242
1.19
0.30
1.1
1.3
24.04
46.27
iu/ml
0.99
11
75
8
106
0.74
0.30
2.5
3.2
—
—
—
0
0
7
56
1.26
0.30
1.1
1.3
—
—
—
0
0
8
110
0.71
0.29
1.1
1.5
—
—
—
0
0
13
104
1.27
0.27
1.1
1.3
—
—
—
0
0
5
37
1.36
0.23
1.8
2.5
—
—
—
0
0
10
124
0.80
0.22
1.1
1.6
—
—
—
0
0
5
41
1.23
0.22
1.2
1.3
—
—
—
0
0
5
42
1.20
0.21
1.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
80.27
—
0
11
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
10
0.00
0.21
0.0
8.2
—
797.30
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
10
80
1.26
0.21
4.6
3.0
1.20
0.17
e6/l
—
10
80
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
2.6
—
468.63
—
0
8
6
53
1.14
0.19
1.2
1.2
—
—
—
0
0
5
66
0.75
0.17
3.6
8.5
—
—
—
0
0
130
1268
1.09
0.17
32.2
17.1
331.45
332.77
g/l
0.94
130
1259
50
471
1.08
0.15
3.9
4.1
—
—
—
0
0
9
80
1.13
0.15
4.6
4.2
—
—
—
0
0
9
82
1.10
0.15
1.2
1.2
—
—
—
0
0
9
82
1.10
0.15
1.3
1.3
—
—
—
0
0
7
87
0.80
0.15
3.0
2.4
—
—
—
0
0
19
172
1.12
0.12
1.3
1.6
—
—
—
0
0
16
144
1.12
0.11
1.3
1.5
—
—
—
0
0
24
222
1.09
0.10
1.7
1.8
—
—
—
0
0
5
44
1.14
0.10
1.6
1.1
—
—
—
0
0
49
511
0.94
0.09
2.1
2.1
168.74
184.17
u/l
0.20
43
468
12
107
1.13
0.08
1.3
1.3
—
36.58
—
0
10
6
57
1.05
0.08
1.2
1.1
—
—
—
0
0
8
91
0.87
0.07
2.5
2.3
1.04
1.25
%
—
8
91
28
293
0.95
0.05
1.1
1.3
2.48
1.81
u/ml
—
5
76
50
514
0.96
0.05
3.4
3.3
—
—
—
0
0
26
269
0.96
0.02
1.3
1.3
1.69
2.82
g/l
3.08
13
157
17
171
0.99
0.00
1.1
1.4
—
—
—
0
0
8
87
0.92
0.00
2.5
2.2
0.65
0.62
%
—
8
87
0
5
0.00
-0.00
0.0
2.8
—
45840.00
—
0
5
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
23.52
—
0
5
0
5
0.00
-0.00
0.0
8.0
—
26.06
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
2.57
—
0
6
0
6
0.00
-0.00
0.0
3.0
—
52.00
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
8.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_KIDNEY_CHROMOPHOBE – Chromophobe cell carcinoma of kidney

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).